Vol. 4 No. 4 (2024)
Reimbursement Reviews

Vutrisiran (Amvuttra)

decorative image of the issue cover

Published April 29, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses vutrisiran (Amvuttra), 25 mg, prefilled syringe, administered via subcutaneous injection.
  • Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis.